Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

In the latest close session, Amgen (AMGN) was up +1.88% at $297.29. The stock outpaced the S&P 500's daily gain of 0.38%. Meanwhile, the Dow experienced a rise of 0.24%, and the technology-dominated ...

Today, Benzinga's options scanner spotted 13 options trades for Amgen. This is not a typical pattern. The sentiment among these major traders is split, with 30% bullish and 61% bearish. Among all the ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Management raised the quarterly dividend 6% to $2.38 per share, resulting in an attractive 3.5% yield at the current stock ...

resulting in an attractive 3.5% yield at the current stock price. The balance sheet remains rock-solid even after the $27.8 billion Horizon Therapeutics acquisition. Amgen reduced debt by $2.8 ...

Many Amgen Inc. (NASDAQ:AMGN) insiders ditched their stock over the past year, which may be of interest to the company's ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.